2023
Sex effects in predictors of smoking abstinence and neuropsychiatric adverse events in the EAGLES trial
McKee S, Lawrence D, Saccone P, McRae T, Anthenelli R. Sex effects in predictors of smoking abstinence and neuropsychiatric adverse events in the EAGLES trial. Drug And Alcohol Dependence Reports 2023, 8: 100177. PMID: 37520849, PMCID: PMC10372180, DOI: 10.1016/j.dadr.2023.100177.Peer-Reviewed Original ResearchNeuropsychiatric adverse eventsCessation outcomesContinuous abstinenceAdverse eventsPsychiatric cohortPsychiatric statusLower oddsEfficacy of vareniclineSmoking cessation medicationsPoint prevalence abstinenceHigher baseline levelsSex effectsLogistic regression modelsEAGLES trialCessation medicationsBaseline characteristicsSmoking historyMedication useNicotine patchPoint prevalenceStudy treatmentBaseline variablesBaseline cigarettesAbstinence outcomesSignificant interaction
2017
Gender differences in the real-world effectiveness of smoking cessation medications: Findings from the 2010–2011 Tobacco Use Supplement to the Current Population Survey
Smith PH, Zhang J, Weinberger AH, Mazure CM, McKee SA. Gender differences in the real-world effectiveness of smoking cessation medications: Findings from the 2010–2011 Tobacco Use Supplement to the Current Population Survey. Drug And Alcohol Dependence 2017, 178: 485-491. PMID: 28715776, PMCID: PMC6779031, DOI: 10.1016/j.drugalcdep.2017.05.046.Peer-Reviewed Original ResearchConceptsTransdermal nicotine patchUnassisted quit attemptsClinical trial dataTobacco Use SupplementQuit attemptsTrial dataClinical trial findingsReal-world effectivenessSample of smokersGender differencesRelevant gender differencesCessation optionsCessation medicationsCessation pharmacotherapyNicotine patchMedication interactionsSmoking cessationPotential confoundersTrial findingsVareniclineComparative effectivenessPropensity scoreCross-sectional dataWomenMedications
2015
Gender Differences in Medication Use and Cigarette Smoking Cessation: Results From the International Tobacco Control Four Country Survey
Smith PH, Kasza KA, Hyland A, Fong GT, Borland R, Brady K, Carpenter MJ, Hartwell K, Cummings KM, McKee SA. Gender Differences in Medication Use and Cigarette Smoking Cessation: Results From the International Tobacco Control Four Country Survey. Nicotine & Tobacco Research 2015, 17: 463-472. PMID: 25762757, PMCID: PMC4402353, DOI: 10.1093/ntr/ntu212.Peer-Reviewed Original ResearchConceptsMedication useInternational Tobacco Control Four Country SurveySmoking cessationFour Country SurveyQuit attemptsCessation medication useCigarette smoking cessationGender differencesAdjusted modelingQuit attemptersNicotine patchSuccessful quittingSubsample of smokersAdult smokersLower oddsCountry SurveyWomenSelf-selected useCessationSmokersSCM useMenWaves 2006Survey wavesVarenicline
2014
Consideration of Sex in Clinical Trials of Transdermal Nicotine Patch: A Systematic Review
Weinberger AH, Smith PH, Kaufman M, McKee SA. Consideration of Sex in Clinical Trials of Transdermal Nicotine Patch: A Systematic Review. Experimental And Clinical Psychopharmacology 2014, 22: 373-383. PMID: 25133506, PMCID: PMC4180800, DOI: 10.1037/a0037692.Peer-Reviewed Original ResearchConceptsTransdermal nicotine patchNicotine patchCessation outcomesClinical trialsSmoking cessationSmoking cessation treatmentMenstrual cycle phaseCessation treatmentSex-related variablesInclusion criteriaMEDLINE searchSmoking treatmentSide effectsBetter outcomesTreatment efficacyConsideration of sexSystematic reviewPotential articlesInclusion of sexSkin irritationMore womenTrialsOutcomesSexWomen
2013
A preliminary study on the effect of combined nicotine replacement therapy on alcohol responses and alcohol self‐administration
Udo T, Harrison EL, Shi J, Tetrault J, McKee SA. A preliminary study on the effect of combined nicotine replacement therapy on alcohol responses and alcohol self‐administration. American Journal On Addictions 2013, 22: 590-597. PMID: 24131167, PMCID: PMC3934424, DOI: 10.1111/j.1521-0391.2013.12014.x.Peer-Reviewed Original ResearchConceptsSelf-administration periodNicotine nasal sprayHeavy drinking smokersNasal sprayNicotine patchAlcohol responsesPriming drinkSerum nicotine levelsPlacebo-controlled studyNicotine replacement therapySubjective alcohol responsesPositive subjective responsesNumber of drinksPlacebo administrationReplacement therapyPriming doseSmoking relapseAlcohol consumptionPlacebo conditionPatch applicationNicotine levelsClinical settingPilot studySmokersSubjective responses
2008
Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation
O'Malley SS, Krishnan-Sarin S, McKee SA, Leeman RF, Cooney NL, Meandzija B, Wu R, Makuch RW. Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. The International Journal Of Neuropsychopharmacology 2008, 12: 589-597. PMID: 18796184, PMCID: PMC3094855, DOI: 10.1017/s146114570800936x.Peer-Reviewed Original ResearchConceptsHazardous drinkingSmoking cessationFavorable side effect profileDose-ranging clinical trialAlcohol useEffects of NTXPlacebo-controlled trialDose-ranging trialSide effect profileTransdermal nicotine patchOpiate antagonist naltrexoneDose-dependent reductionComponent of treatmentHazardous alcohol useOral NTXSecondary outcomesNicotine patchPrimary outcomeAntagonist naltrexoneCombination therapyClinical trialsBaseline predictorsOral preparationsHazardous drinkersNTX
2007
Factor structure and validity of the Medication Adherence Questionnaire (MAQ) with cigarette smokers trying to quit.
Toll BA, McKee SA, Martin DJ, Jatlow P, O'Malley SS. Factor structure and validity of the Medication Adherence Questionnaire (MAQ) with cigarette smokers trying to quit. Nicotine & Tobacco Research 2007, 9: 597-605. PMID: 17454716, PMCID: PMC2527736, DOI: 10.1080/14622200701239662.Peer-Reviewed Original ResearchConceptsMedication Adherence QuestionnaireCigarette smokersNicotine patchAdherence QuestionnaireMedication adherenceNicotine patch useSmoking cessation outcomesPill-taking behaviorSample of smokersDrug plasma levelsBrief screening toolNonadherence factorsMedication useUnintentional nonadherencePlasma levelsCessation outcomesClinical trialsTreatment outcomesDrug levelsPredictive validitySmokersMAQ scoresNonadherenceScreening toolFactor 1
2006
A Controlled Trial of Naltrexone Augmentation of Nicotine Replacement Therapy for Smoking Cessation
O’Malley S, Cooney JL, Krishnan-Sarin S, Dubin JA, McKee SA, Cooney NL, Blakeslee A, Meandzija B, Romano-Dahlgard D, Wu R, Makuch R, Jatlow P. A Controlled Trial of Naltrexone Augmentation of Nicotine Replacement Therapy for Smoking Cessation. JAMA Internal Medicine 2006, 166: 667-674. PMID: 16567607, DOI: 10.1001/archinte.166.6.667.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAmbulatory CareDose-Response Relationship, DrugDouble-Blind MethodDrug Therapy, CombinationFemaleHumansLinear ModelsMaleMiddle AgedNaltrexoneNarcotic AntagonistsNicotineNicotinic AgonistsSmoking CessationSubstance Withdrawal SyndromeSurveys and QuestionnairesTreatment OutcomeWeight GainConceptsNicotine patch therapyNicotine patchPatch therapyDouble-blind placebo-controlled trialHigher continuous abstinence ratesLow-dose naltrexone therapyNaltrexone hydrochlorideWeight gainTreatment completersOral naltrexone hydrochlorideOutpatient research centerWeight-concerned smokersContinuous abstinence ratesPlacebo-controlled trialPrimary end pointSecond-line treatmentNicotine replacement therapyNaltrexone augmentationNaltrexone therapyPlacebo groupQuit dateTreat analysisAbstinence ratesReplacement therapySmoking cessation